Literature DB >> 25516552

Comparison of the physiological relevance of systemic vs. portal insulin delivery to evaluate whole body glucose flux during an insulin clamp.

Tiffany D Farmer1, Erin C Jenkins2, Tracy P O'Brien2, Gregory A McCoy2, Allison E Havlik1, Erik R Nass1, Wendell E Nicholson3, Richard L Printz4, Masakazu Shiota5.   

Abstract

To understand the underlying pathology of metabolic diseases, such as diabetes, an accurate determination of whole body glucose flux needs to be made by a method that maintains key physiological features. One such feature is a positive differential in insulin concentration between the portal venous and systemic arterial circulation (P/S-IG). P/S-IG during the determination of the relative contribution of liver and extra-liver tissues/organs to whole body glucose flux during an insulin clamp with either systemic (SID) or portal (PID) insulin delivery was examined with insulin infusion rates of 1, 2, and 5 mU·kg(-1)·min(-1) under either euglycemic or hyperglycemic conditions in 6-h-fasted conscious normal rats. A P/S-IG was initially determined with endogenous insulin secretion to exist with a value of 2.07. During an insulin clamp, while inhibiting endogenous insulin secretion by somatostatin, P/S-IG remained at 2.2 with PID, whereas, P/S-IG disappeared completely with SID, which exhibited higher arterial and lower portal insulin levels compared with PID. Consequently, glucose disappearance rates and muscle glycogen synthetic rates were higher, but suppression of endogenous glucose production and liver glycogen synthetic rates were lower with SID compared with PID. When the insulin clamp was performed with SID at 2 and 5 mU·kg(-1)·min(-1) without managing endogenous insulin secretion under euglycemic but not hyperglycemic conditions, endogenous insulin secretion was completely suppressed with SID, and the P/S-IG disappeared. Thus, compared with PID, an insulin clamp with SID underestimates the contribution of liver in response to insulin to whole body glucose flux.
Copyright © 2015 the American Physiological Society.

Entities:  

Keywords:  insulin clamp method; liver; muscle; portal-systemic insulin gradient

Mesh:

Substances:

Year:  2014        PMID: 25516552      PMCID: PMC4312835          DOI: 10.1152/ajpendo.00406.2014

Source DB:  PubMed          Journal:  Am J Physiol Endocrinol Metab        ISSN: 0193-1849            Impact factor:   4.310


  96 in total

1.  Restoration of liver insulin signaling in Insr knockout mice fails to normalize hepatic insulin action.

Authors:  Haruka Okamoto; Silvana Obici; Domenico Accili; Luciano Rossetti
Journal:  J Clin Invest       Date:  2005-05       Impact factor: 14.808

2.  Molecular disruption of hypothalamic nutrient sensing induces obesity.

Authors:  Wu He; Tony K T Lam; Silvana Obici; Luciano Rossetti
Journal:  Nat Neurosci       Date:  2006-01-15       Impact factor: 24.884

3.  Mice lacking adiponectin show decreased hepatic insulin sensitivity and reduced responsiveness to peroxisome proliferator-activated receptor gamma agonists.

Authors:  Andrea R Nawrocki; Michael W Rajala; Eva Tomas; Utpal B Pajvani; Asish K Saha; Myrna E Trumbauer; Zhen Pang; Airu S Chen; Neil B Ruderman; Howard Chen; Luciano Rossetti; Philipp E Scherer
Journal:  J Biol Chem       Date:  2005-12-02       Impact factor: 5.157

4.  A defect in glucose-induced dissociation of glucokinase from the regulatory protein in Zucker diabetic fatty rats in the early stage of diabetes.

Authors:  Jun-Seop Shin; Tracy P Torres; Reetta L Catlin; E P Donahue; Masakazu Shiota
Journal:  Am J Physiol Regul Integr Comp Physiol       Date:  2007-01-04       Impact factor: 3.619

5.  Mechanisms of impaired fasting glucose and glucose intolerance induced by an approximate 50% pancreatectomy.

Authors:  Aleksey V Matveyenko; Johannes D Veldhuis; Peter C Butler
Journal:  Diabetes       Date:  2006-08       Impact factor: 9.461

6.  Glucose toxicity is responsible for the development of impaired regulation of endogenous glucose production and hepatic glucokinase in Zucker diabetic fatty rats.

Authors:  Yuka Fujimoto; Tracy P Torres; E Patrick Donahue; Masakazu Shiota
Journal:  Diabetes       Date:  2006-09       Impact factor: 9.461

7.  Euglycemic hyperinsulinemic clamp to assess posthepatic glucose appearance after carbohydrate loading. 1. Validation in pigs.

Authors:  V Lang; P Vaugelade; F Bernard; B Darcy-Vrillon; C Alamowitch; G Slama; P H Duée; F R Bornet
Journal:  Am J Clin Nutr       Date:  1999-06       Impact factor: 7.045

8.  Considerations in the design of hyperinsulinemic-euglycemic clamps in the conscious mouse.

Authors:  Julio E Ayala; Deanna P Bracy; Owen P McGuinness; David H Wasserman
Journal:  Diabetes       Date:  2006-02       Impact factor: 9.461

9.  Pulsatile insulin secretion dictates systemic insulin delivery by regulating hepatic insulin extraction in humans.

Authors:  Juris J Meier; Johannes D Veldhuis; Peter C Butler
Journal:  Diabetes       Date:  2005-06       Impact factor: 9.461

10.  Beta-cell "rest" accompanies reduced first-pass hepatic insulin extraction in the insulin-resistant, fat-fed canine model.

Authors:  Stella P Kim; Martin Ellmerer; Erlinda L Kirkman; Richard N Bergman
Journal:  Am J Physiol Endocrinol Metab       Date:  2007-02-06       Impact factor: 4.310

View more
  15 in total

1.  Screening for non-alcoholic fatty liver disease in children and adolescents with type 1 diabetes mellitus: a cross-sectional analysis.

Authors:  Sebastian Kummer; Dirk Klee; Gerald Kircheis; Michael Friedt; Joerg Schaper; Dieter Häussinger; Ertan Mayatepek; Thomas Meissner
Journal:  Eur J Pediatr       Date:  2017-02-17       Impact factor: 3.183

2.  Multi-dimensional Transcriptional Remodeling by Physiological Insulin In Vivo.

Authors:  Thiago M Batista; Ruben Garcia-Martin; Weikang Cai; Masahiro Konishi; Brian T O'Neill; Masaji Sakaguchi; Jong Hun Kim; Dae Young Jung; Jason K Kim; C Ronald Kahn
Journal:  Cell Rep       Date:  2019-03-19       Impact factor: 9.423

3.  Targeting insulin to the liver corrects defects in glucose metabolism caused by peripheral insulin delivery.

Authors:  Dale S Edgerton; Melanie Scott; Ben Farmer; Phillip E Williams; Peter Madsen; Thomas Kjeldsen; Christian L Brand; Christian Fledelius; Erica Nishimura; Alan D Cherrington
Journal:  JCI Insight       Date:  2019-02-26

Review 4.  Tissue barriers and novel approaches to achieve hepatoselectivity of subcutaneously-injected insulin therapeutics.

Authors:  Juntang Shao; Jennica L Zaro; Wei-Chiang Shen
Journal:  Tissue Barriers       Date:  2016-03-04

5.  Insulin's direct hepatic effect explains the inhibition of glucose production caused by insulin secretion.

Authors:  Dale S Edgerton; Guillaume Kraft; Marta Smith; Ben Farmer; Phillip E Williams; Katie C Coate; Richard L Printz; Richard M O'Brien; Alan D Cherrington
Journal:  JCI Insight       Date:  2017-03-23

Review 6.  Derivatization with fatty acids in peptide and protein drug discovery.

Authors:  Peter Kurtzhals; Søren Østergaard; Erica Nishimura; Thomas Kjeldsen
Journal:  Nat Rev Drug Discov       Date:  2022-08-24       Impact factor: 112.288

7.  Detection of insulins in postmortem tissues: an optimized workflow based on immunopurification and LC-MS/HRMS detection.

Authors:  Charline Bottinelli; Fabien Bévalot; Nathalie Cartiser; Laurent Fanton; Jérôme Guitton
Journal:  Int J Legal Med       Date:  2021-05-01       Impact factor: 2.686

Review 8.  Brain insulin signalling in metabolic homeostasis and disease.

Authors:  Thomas Scherer; Kenichi Sakamoto; Christoph Buettner
Journal:  Nat Rev Endocrinol       Date:  2021-06-09       Impact factor: 43.330

9.  The Importance of the Mechanisms by Which Insulin Regulates Meal-Associated Liver Glucose Uptake in the Dog.

Authors:  Guillaume Kraft; Katie C Coate; Marta Smith; Ben Farmer; Melanie Scott; Alan D Cherrington; Dale S Edgerton
Journal:  Diabetes       Date:  2021-03-23       Impact factor: 9.337

10.  Is brain insulin action relevant to the control of plasma glucose in humans?

Authors:  Dale S Edgerton; Alan D Cherrington
Journal:  Diabetes       Date:  2015-03       Impact factor: 9.461

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.